Moderna is recruiting adult participants for Nova 301, its Phase 3 clinical trial evaluating an investigational norovirus vaccine called mRNA-1403. “Norovirus is a significant public health concern ...
Online content falsely claiming vaccines can be distributed through the food supply has circulated for years and a new series ...
StockStory.org on MSN
Why Moderna (MRNA) stock is trading up today
What Happened? Shares of biotechnology company Moderna (NASDAQ:MRNA) jumped 2.6% in the afternoon session after the European ...
Moderna (NASDAQ:MRNA) stock is jumping again. Shares are up 9% today, trading near $57 in the Tuesday afternoon session. That extends a remarkable 2026 run for the mRNA pioneer. The move pushes ...
Moderna's growth story is just beginning.
VRBPAC endorsed mRNA-1010 for adults 50-64 and ≥65 years, unanimously concluding benefits outweighed risks, supporting a late-stage regulatory path toward potential first mRNA seasonal influenza ...
An experimental mRNA vaccine delayed neuroblastoma growth and sharply reduced tumor size in preclinical models.
Researchers found that mRNA cancer vaccines can recruit an unexpected immune cell to launch powerful tumor-fighting responses ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results